Deciphera Pharmaceuticals LLC

Lawrence, KS, United States

Deciphera Pharmaceuticals LLC

Lawrence, KS, United States

Time filter

Source Type

It has been shown that Compound 1 unexpectedly and potently inhibits TIE2 kinase, and that Compound 1 inhibits drug resistance mechanisms in both the tumor and in the surrounding microenvironment through balanced inhibition of TIE2, MET, and VEGFR2 kinases. Thus, Compound 1 provides a single therapeutic agent able to address multiple hallmarks of cancer by inhibiting TIE2, MET, and VEGFR2 kinases in the tumor microenvironment [Hanahan 2011]. Through its balanced inhibitory potency vs TIE2, MET, and VEGFR2, Compound 1 provides an agent which inhibits three major tumor (re)vascularization and resistance pathways (ANG, HGF, VEGF) and blocks tumor invasion and metastasis. Compound 1 exhibits anti-tumor activity alone and in combination with other targeted agents or chemotherapy.


Patent
Deciphera Pharmaceuticals Llc | Date: 2016-08-31

The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravasation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.


Patent
Deciphera Pharmaceuticals LLC | Date: 2015-11-11

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein ab1 kinase protein, bcr-ab1 kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.


Patent
Deciphera Pharmaceuticals Llc | Date: 2015-10-14

It has been shown that Compound 1 unexpectedly and potently inhibits TRK kinases, including all three forms of TRK: NTRK1, NTRK2, and NTRK3. Additionally it has been shown that Compound 1 potently inhibits oncogenic mutated forms of TRK kinases, including fusion proteins. By way of exemplification, Compound 1 potently inhibits the NTRK1 oncogenic fusion protein TPM3/NTRK1 in cellular assays. Compound 1 inhibits TRK kinase mediated tumor growth in vivo in a TPM3/NTRK1 xenograft model.


Patent
Deciphera Pharmaceuticals LLC | Date: 2014-03-14

Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.


Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.


Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.


Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.


Patent
Deciphera Pharmaceuticals LLC | Date: 2015-08-03

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.


The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed:

Loading Deciphera Pharmaceuticals LLC collaborators
Loading Deciphera Pharmaceuticals LLC collaborators